Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1 1

Status

Recruiting 2Completed 2Withdrawn 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Motor Activity 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia 1

Interventions

pembrolizumab 555Specimen Handling 459Carboplatin 446Magnetic Resonance Spectroscopy 427Cyclophosphamide 412Cisplatin 404Gemcitabine 314Radiotherapy 313Bevacizumab 310Paclitaxel 300Biopsy 260Drug Therapy 252Capecitabine 241Oxaliplatin 240fludarabine 236Nivolumab 226venetoclax 225Injections 214Docetaxel 203Fluorouracil 201Dexamethasone 186Radiosurgery 172Rituximab 161Pemetrexed 157durvalumab 144Standard of Care 143atezolizumab 139toripalimab 137tislelizumab 137Leucovorin 137

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Interventional × Roflumilast × Clear all
NCT06977711 2025-08-05

Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)

The University of Texas Health Science Center at San Antonio

Phase 1 Recruiting
10 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT06643221 2024-10-16

Allo-X

University of Arizona

Phase EARLY_PHASE1 Recruiting
100 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Motor Activity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡